FINHUB Insights

ABBV · Q2 FY25 · Apr 1 – Jun 30, 2025

AbbVie Q2 FY25: where the revenue came from and where it went

AbbVie Q2 FY25: revenue $15.4B (+7% year over year). Net profit $0.9B. Largest cohort Skyrizi $4.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 4, 2025 10-Q
Sankey diagram of AbbVie's income statement for Q2 FY25: revenue of $15.4 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$15.4B +7% year over year
Gross profit$11.1B 72% margin
Operating profit$4.9B 32% margin
Net profit$0.9B 6% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 15.4 100% +7%
Skyrizi 4.4 29% +62%
Neuroscience 2.7 18% +24%
Rinvoq 2 13% +42%
Oncology 1.7 11%
Other 1.3 8%
Aesthetics 1.3 8% −8%
Humira 1.2 8% −58%
Other Key Products 0.8 5% −14%
Cost of revenue−4.328%
Gross profit11.172% margin+1pp
SG&A−3.321%−2pp
Other−2.919%+0pp
Operating profit4.932% margin+4pp
Tax−0.6
Interest & other costs−3.4
Net profit0.96%−3pp
Filing on EDGAR More quarters of ABBV

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters